99 results about "Huperzine U" patented technology

The invention provides a method for extracting high-purity huperzine A and huperzine B from medicinal plant phlegmariurus crutomerianus, which greatly increases the basis for extracting the huperzine A and the huperzine B from new species. The invention discloses an overall method for separating and extracting the high-purity huperzine A and the high-purity huperzine B from the phlegmariurus crutomerianus. Pure products of the huperzine A and the huperzine B are obtained by adopting acid water extraction, passing ion exchange resin, concentrating, leaching, performing reverse-phase column chromatography, decoloring by using activated carbon, crystallizing and recrystallizing. In the overall separation process, requirements on environmental conditions are low, the separation time is short, and the purity is highest. Separation materials are easy to obtain and cheap; a separation operation process is simple and easy to control; the purification efficiency is high by crystallizing and recrystallizing; and used reagents are nontoxic.

The invention relates to a method for extracting and separating huperzine A and huperzine B from huperzia serrata, which comprises total huperzine extraction and purification, and huperzine A/huperzine B separation and crystallization. The invention has the following advantages: acid soaking and ultrasonic repeated extraction can sufficiently precipitate total huperzines in the huperzia serrata; activated carbon and cation exchange resin are utilized to remove impurities; reversion phase chromatography columns are utilized to separate huperzine A and huperzine B; and concentration crystallization and recrystallization are respectively utilized to enhance the purity of the huperzine A and huperzine B. The invention effectively utilizes natural resources, enhances the recovery rate and extract content, and improves the economic benefit.

The invention discloses a huperzine A polymorph, its preparation method, a medicinal composition containing huperzine A polymorph and its application. Part of the huperzine A polymorph has better dissolvability than currently saled medicinal crystal forms, thus being more conducive to medicine absorption. Also, part of the huperzine A polymorph has substantially lower hygroscopicity than saled medicinal crystal forms, thus being more conducive to preparation and storage of medicinal preparations.

The invention discloses a huperzia serrate endophytic fungus which is obtained from a pteridophyte, namely, a huperzia serrate plant by adopting a separating and purifying technology, is named Ceriporia lacerate HS-ZJUT-C13A and is collected in the China Center for Type Culture Collection on October 28, 2012 with the collection number CCTCC M 2012433. The strain provided by the invention can be used for preparing a compound, namely, 8alpha, 15alpha-epoxydized huperzine A with a nerve protection effect. A conversion method has the advantages of simple fermentation conditions, high substrate conversion rate and the like, is easily cultures the strain, has the potential of industrial large-scale production, is a novel way for obtaining the compound, protects valuable and rare medicinal huperziaceae plant resources from being damaged and can provide a novel thought for reliving the current situation of lack of huperzine A in clinical administration.

The invention discloses an extraction method of huperzine A. The extraction method comprises the following steps: fermentation treatment of leaves of huperzia serrata, diethyl ether soaking, centrifugation, water bath evaporation and cooling crystallization. By virtue of the extraction method, the yield and extraction purity of huperzine A can be greatly increased, and furthermore, the production cost is low; and the extraction method is suitable for industrial production.

The invention discloses a method for hydroponic breeding of huperzine serrate and induced improvement to huperzine a of the huperzine serrate. According to the method, wild naturalized huperzine-serrate branches with stem tips are used as cuttings, and rapid hydroponic breeding of the huperzine serrate is achieved in a nutrient solution containing hormones and precursor substances with a certain ratio; compared with conventional soil cutting, the method realizes that rooting time is short, the breeding coefficient is large, and the rooting percentage is as high as 98%. The precursor substances enable the huperzine a content of the hydroponic huperzine serrate to be increased by 70% compared with wild plants; the leaf surfaces or/and the roots of the plants are sprinkled with elicitors in a certain concentration, so that a secondary metabolism system of the huperzine serrate is regulated, the huperzine a content of the hydroponic huperzine serrate is increased 1.3-1.6 times, the yield of the huperzine a is increased, and the situation of shortage of huperzine-serrate resources is alleviated to a certain degree. Besides, the method achieves low production cost and a short cultivation period, is not restricted by the natural environment and climate, and has broad application prospects and high popularization value.

A concentration and mental performance amplifying formulation comprising rhodiola rosea and geranium oil, together with at least one of vinpocetine, phosphatidylcholine, caffeine and Salix alba (White Willow Bark). In another aspect, there is disclosed a concentration and mental performance amplifying formulation comprising: rhodiola rosea, geranium oil, and at least one of anhydrous caffeine and nicotine. In yet another aspect, there is disclosed a concentration and mental performance amplifying formulation as last described which further comprises: Vinpocetine, or Vincamine together with Huperzine-A, or Vinca minor (Periwinkle) together with Huperzine-A; PhosphatidylCholine or Bacopa monnieri (Brahmi) or Mucuna pruriens; Nicotinamide Adenine Dinucleotide Hydrate; and Salix alba (White Willow Bark). Also described is a method of amplifying concentration and mental performance in a human subject by administering such formulations to such a subject.

The invention discloses a huperzine A double-layer osmotic pump controlled-release tablet. The tablet comprises a double-layer tablet core consisting of a drug containing layer and a pushing layer, and a semipermeable coating membrane coating the double-layer tablet core, wherein one side of the drug containing layer of the coating membrane is provided with a drug release hole; the drug containing layer of the tablet core contains huperzine, a suspending agent, osmotic pressure active matters and pharmaceutical excipients which are all in effective dosage; the pushing layer contains an expanding agent, a permeation enhancer, and a binder; and the coating membrane contains polyethylene glycol used as a plasticizer, the weight gain of the coating membrane against the weight of the tablet core is between 8 and 20 percent, and the aperture of the drug release hole on the surface of the drug containing layer of the coating membrane is between 0.2 and 2.0 millimeters. The invention also discloses a method for preparing the controlled-release tablet. After patients take the controlled-release tablet, the blood concentration of the patients is relatively stable; the accumulated drug release rate in 12 hours reaches more than 90 percent, thereby greatly reducing the drug taking frequency of the patients; and the invention provides a novel formulation which is safer, more effective, stable, controllable and convenient for application in clinically treating senile dementia.

The invention discloses a method for producing huperzine A by using huperzia serrata prothallium. The huperzine A is produced from in vitro huperzia serrata prothallium by mass culture. The method is simple and easy to operate, provides new ways for sources of the huperzine A, and protects resource of wild huperzia serrata simultaneously.

The invention discloses a method for extracting huperzine A from a serrate clubmoss herb. The method comprises the following steps: (1) pre-treatment; (2) ultrasonic countercurrent extraction: carrying out ultrasonic countercurrent extraction on the serrate clubmoss herb and filtering to obtain leach liquor; (3) membrane separation and purification: centrifuging, and carrying out ultrafiltration and nanofiltration on the leach liquor to obtain trapped fluid; (4) concentration, namely concentrating the trapped fluid into paste; (5) acid dissolution, dissolving the paste by using acid liquid, filtering, and adjusting pH to alkalinity; (6) extraction: extracting by using chloroform and collecting extract liquor; (7) concentration: concentrating the extract liquor to obtain dry powder; (8) crystallization and recrystallization: dissolving to obtain the dry powder, crystallizing and recrystallizing to obtain white crystals; and (9) drying, namely drying the white crystal to obtain a huperzine A product. According to the method disclosed by the invention, the purity of the huperzine A extracted from the serrate clubmoss herb is greater than or equal to 99%, the product yield is greater than or equal to 0.026%, the final yield is 50-55%, and the yield, yield coefficient and purity of huperzine A is high, the extraction time is short, and the cost is low; therefore, the method for extracting huperzine A from a serrate clubmoss herb is suitable for industrial production.

The invention relates to a novel method for extracting huperzine A from Huperziaserrataf.longipetiolata (Spring) Ching, and relates to the technical field of medicines. The novel method comprises the technical scheme as follows: (1) preparing extracting liquid; (2) purifying the extracting liquid; (3) preparing the total alkaloid of huperzia serrata; (4) preparing a rough product of huperzine A; and (5) preparing high-purity huperzine A, thus obtaining the white solid huperzine A with the purity of 98% to 99%. The novel method of extracting the huperzine A provided by the invention has the advantages that: (1) the new resource huperzia serrata is served as the raw material; and the single source of the medicine and technology method for extracting huperzine A from huperziaserrataf.longipetiolata (Spring) Ching are expanded; (2) 20% to 60% of ethanol water is adopted for extracting, therefore, little damage is brought to instruments and equipment, and low toxic and side effects are generated; and (3) the huperzine A is enriched through a reverse phase (Middle Pressure Liquid Chromatography) is adopted, thus, the cost is low, the purity is high, the yield is high, and the mass industrial production can be easily carried out.

The invention discloses application and a preparation method of huperzine A gelatin nanoparticle loaded microspheres. According to drug release amount requirements of huperzine A and drug release characteristics of nanoparticles and microspheres, nanoparticles and microsphere preparations are combined so as to solve the problem of burst release of huperzine A sustained-release preparations, and sustained release is realized.

An oral disintegrating tablet of huperzine A contains proportionally huperzine A as the cholinesterase depressant, mannitol as diluent and the alcohol solution of PVP-K30 as adhesive. Its preparing process is also disclosed.

The invention provides a bacillus amyloliquefaciens SXZ-N2 strain producing huperzine A and huperzine B. The strain can produce huperzine A and huperzine B. The strain is named as SXZ-N2 and belongs to bacillus amyloliquefaciens. The strain is collected in China Center for Type Culture Collection (CCTCC) on September 14, 2017 in Wuhan University, Wuhan, China, with a postal code of 430072 and a collection number of CCTCC NO: M2017510. A 16S rDNA sequence of the strain is shown as SEQ ID (sequence identifier) NO. 1. The bacillus amyloliquefaciens SXZ-N2 strain can be used for fermentation preparation of huperzine A and huperzine B. Microbial fermentation conditions are as follows: a formula of a culture medium comprises 5g/L yeast powder, 6g/L peptone, 5g/L sodium chloride and 8g/L sucrose; a pH (potential of hydrogen) is 8.0, culture conditions are as follows: 32 DEG C, 150r/min, and fermentation culture lasts for 10 days.

A composition for increasing GH levels in a mammal including effective amounts of huperzine A and secretagogue amino acids and methods thereof.

The present invention discloses a drug composition for enhancing memory of people rapidly exposed to a high altitude. The drug composition comprises an active component and an auxiliary material, wherein the active component comprises taurine, ovolecithin, acetyl-L-carnitine, and huperzine a, and the auxiliary material comprises lactose, MCC and magnesium stearate, or comprises lactose and magnesium stearate. The drug composition has the following beneficial effects that: based on different mechanisms such as provision of essential nutrients for nerve cells, free radical removing, neurotransmitter acetylcholine precursor complementing, central cholinergic system regulation, and the like, a comprehensive effect is acted on human body, drug combination advantages are presented, and improvement of memory of people rapidly exposed to a high altitude is achieved.

The invention relates to application of Huperzine A in preparing medicaments, namely the application of the Huperzine A in preparing medicaments for preventing and treating glaucoma, increase of intraocular pressure and eye problems concomitant with retinal ganglion cell injury. The invention has the advantages that: 1, the new medical treatment application of the Huperzine A is developed, and a new application field is exploited; 2, the Huperzine A is safe and non-toxic, and has strong pharmacological effects, and good medicinal prospect of the Huperzine A is predicted; and 3, a great deal of cell and animal experimental study proves that the medicament Huperzine A has good effects of protecting retinal ganglion cell and reducing the intraocular pressure by oral administration and local eye dropping, and can be used for preventing and treating the glaucoma, the increase of intraocular pressure and the eye problems concomitant with retinal ganglion cell injury.

The invention relates to huperzia serrata endophyte and application of the huperzia serrata endophyte. The huperzia serrata endophyte is characterized in that the endophyte is taxonomically named as Schizophyllum commune, named as XQYS, and preserved in the general microbiology centre of China Committee for Culture Collection of Microorganisms at Dec. 5th, 2011; the preservation number is CGMCC No.5510; a rRNA (ribosomal ribonucleic acid) gene sequence of fungus for producing huperzine A includes complete sequences of 18S rRNA segment, ITS1, 5.8S rRNA and ITS2, and a segment of 28S rRNA sequence. Application of the huperzia serrata endophyte in preparation of the huperzine A is provided.